XBiotech Past Earnings Performance
Past criteria checks 0/6
XBiotech's earnings have been declining at an average annual rate of -45.4%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been declining at an average rate of 6.8% per year.
Key information
-45.4%
Earnings growth rate
-44.9%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | -6.8% |
Return on equity | -11.2% |
Net Margin | n/a |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
We're Not Very Worried About XBiotech's (NASDAQ:XBIT) Cash Burn Rate
Feb 09We're Hopeful That XBiotech (NASDAQ:XBIT) Will Use Its Cash Wisely
Oct 25We Think Some Shareholders May Hesitate To Increase XBiotech Inc.'s (NASDAQ:XBIT) CEO Compensation
Jun 16XBiotech (NASDAQ:XBIT) Is In A Good Position To Deliver On Growth Plans
May 11Read This Before Buying XBiotech Inc. (NASDAQ:XBIT) Shares
Mar 18Here's Why We Don't Think XBiotech's (NASDAQ:XBIT) Statutory Earnings Reflect Its Underlying Earnings Potential
Jan 08XBiotech's influenza-COVID-19 therapeutic cocktail shows effective anti-virus activity
Nov 19Revenue & Expenses BreakdownBeta
How XBiotech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 0 | -25 | 5 | 33 |
30 Sep 23 | 0 | -23 | 5 | 32 |
30 Jun 23 | 2 | -28 | 5 | 32 |
31 Mar 23 | 4 | -31 | 6 | 31 |
31 Dec 22 | 4 | -33 | 6 | 32 |
30 Sep 22 | 8 | -36 | 7 | 33 |
30 Jun 22 | 11 | -27 | 8 | 32 |
31 Mar 22 | 14 | -20 | 9 | 30 |
31 Dec 21 | 18 | -17 | 9 | 28 |
30 Sep 21 | 19 | -13 | 12 | 23 |
30 Jun 21 | 25 | -12 | 14 | 20 |
31 Mar 21 | 36 | -14 | 16 | 13 |
31 Dec 20 | 44 | -11 | 18 | 10 |
30 Sep 20 | 39 | 677 | 17 | 16 |
30 Jun 20 | 28 | 673 | 15 | 19 |
31 Mar 20 | 13 | 674 | 10 | 21 |
31 Dec 19 | 0 | 669 | 7 | 24 |
30 Sep 19 | 0 | -24 | 5 | 19 |
30 Jun 19 | 0 | -23 | 5 | 18 |
31 Mar 19 | 0 | -23 | 5 | 17 |
31 Dec 18 | 0 | -21 | 5 | 16 |
30 Sep 18 | 0 | -22 | 6 | 17 |
30 Jun 18 | 0 | -23 | 6 | 17 |
31 Mar 18 | 0 | -27 | 7 | 21 |
31 Dec 17 | 0 | -33 | 8 | 26 |
30 Sep 17 | 0 | -42 | 9 | 34 |
30 Jun 17 | 0 | -49 | 10 | 39 |
31 Mar 17 | 0 | -53 | 10 | 43 |
31 Dec 16 | 0 | -53 | 11 | 42 |
30 Sep 16 | 0 | -48 | 9 | 39 |
30 Jun 16 | 0 | -47 | 8 | 39 |
31 Mar 16 | 0 | -40 | 7 | 32 |
31 Dec 15 | 0 | -37 | 6 | 31 |
30 Sep 15 | 0 | -32 | 7 | 25 |
30 Jun 15 | 0 | -28 | 9 | 19 |
31 Mar 15 | 0 | -25 | 7 | 18 |
31 Dec 14 | 0 | -22 | 8 | 14 |
30 Sep 14 | 0 | -18 | 6 | 12 |
Quality Earnings: XBIT is currently unprofitable.
Growing Profit Margin: XBIT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: XBIT is unprofitable, and losses have increased over the past 5 years at a rate of 45.4% per year.
Accelerating Growth: Unable to compare XBIT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: XBIT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: XBIT has a negative Return on Equity (-11.22%), as it is currently unprofitable.